Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/09/2019 01/10/2019 01/11/2019 01/14/2019 01/15/2019 Date
43.34(c) 42.31(c) 42.88(c) 42.37(c) 42.73(c) Last
19 077 393 37 695 611 19 985 293 16 703 162 24 341 651 Volume
-0.21% -2.38% +1.35% -1.19% +0.85% Change
More quotes
Financials (USD)
Sales 2018 53 590 M
EBIT 2018 20 023 M
Net income 2018 13 007 M
Debt 2018 28 504 M
Yield 2018 3,23%
Sales 2019 54 502 M
EBIT 2019 20 675 M
Net income 2019 13 604 M
Debt 2019 28 562 M
Yield 2019 3,41%
P/E ratio 2018 17,73
P/E ratio 2019 17,53
EV / Sales2018 5,12x
EV / Sales2019 5,03x
Capitalization 246 B
More Financials
Company
Pfizer the world's leading pharmaceutical group. Net sales break down by family of products as follows: - vaccines, oncology products and consumer medicines (59.8%); - generic medicines (40.2%): for treating cardio-vascular diseases, nervous system disorders, infectious and respiratory... 
Sector
Pharmaceuticals
Calendar
01/29 | 06:45amEarnings Release
More about the company
Surperformance© ratings of Pfizer
Trading Rating : Investor Rating :
More Ratings
Latest news on PFIZER
04:36aBeiGene's Btk inhibitor gets U.S. breakthrough designation
AQ
04:10aPFIZER : US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat ..
AQ
01/14PFIZER : FDA Accepts NDAs for Tafamidis in ATTR-CM
DJ
01/14PFIZER : US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat ..
BU
01/12PFIZER : inks tech deal with VN company
AQ
01/12PFIZER : CytoReason teams with Pfizer on drug discovery
AQ
01/11PFIZER : Statement of Changes in Beneficial Ownership
PU
01/10AMERISOURCEBERGEN : US government recovered $2.5B from Medicare, Medicaid fraud ..
AQ
01/10PFIZER : to stop manufacturing in its Chennai and Aurangabad facilities
AQ
01/10AMERISOURCEBERGEN : US government recovered $2.5B from Medicare, Medicaid fraud ..
AQ
More news
Analyst Recommendations on PFIZER
More recommendations
Sector news : Pharmaceuticals - NEC
02:44pEuropean nations weigh impact of Brexit on drug supplies
RE
02:09pDrug companies greet 2019 with U.S. price hikes
RE
12:23pFrench court cancels Monsanto weedkiller permit on safety grounds
RE
12:19pBAYER : Faces New Setback for Roundup Weedkiller in France
DJ
12:17pBritish shares up on China stimulus hopes, all eyes on Brexit deal vote
RE
More sector news : Pharmaceuticals - NEC
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 45,3 $
Spread / Average Target 7,0%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-1.76%245 746
JOHNSON & JOHNSON0.54%344 044
ROCHE HOLDING LTD.4.13%221 817
NOVARTIS1.59%221 313
MERCK AND COMPANY-3.98%190 790
AMGEN1.08%125 392